Objectives: To determine the in vitro stability and efficacy of colistin, tigecycline and levofloxacin alone or in combination with clarithromycin and/or heparin as lock solutions against biofilm-embedded Acinetobacter baumannii strains.
Introduction
The use of central venous catheters (CVCs) has dramatically increased during the last decade worldwide. Catheter-related bacteraemia (CRB) infections associated with the insertion and maintenance of CVCs are among the most common and dangerous complications that can occur. When CRB is diagnosed, the guidelines recommended that the patients for whom CVCs cannot be removed should be treated for 2 weeks with systemic therapy and antibiotic lock therapy (ALT), as they often suffer from Gram-negative bacteraemia. 1 ALT is based on the instillation of high concentrations of an antimicrobial agent into the lumens of infected CVCs for extended periods to overcome the relative antimicrobial resistance of biofilm bacteria. 2 -4 Although most investigations have focused on CVC infections involving Gram-positive bacteria, Gram-negatives are also important pathogens in catheter-related infections. 5 -7 Gramnegative bacteria accounted for 19% and 21% of CRBs reported to the CDC 8 and the Surveillance and Control of Pathogens of Epidemiological Importance ('SCOPE') database, 9 respectively. Acinetobacter baumannii is an important organism that causes catheter-related infections and often difficult-to-eradicate bloodstream infections.
6,10 Seifert et al. 11 showed that of patients with A. baumannii bacteraemia, 91% were hospitalized in an intensive care unit (ICU) and 99% had indwelling vascular catheters.
In the present study, we examined the in vitro activity of ALT using colistin, tigecycline and levofloxacin alone or in combination with clarithromycin and/or heparin, an anticoagulant agent, against biofilm-embedded A. baumannii. 
Materials and methods

Bacterial strains used
A. baumannii AB-1 was isolated from patients with CRB. A. baumannii ATCC 19606 (AB-19606) is known to form biofilms. These two strains were confirmed for biofilm-forming ability.
Determination of MICs
MICs were determined by the broth microdilution method according to the CLSI guidelines.
12 AB-19606 was used as a control strain.
In vitro antibiotic lock model
Segments (1 cm) of 7-French, triple-lumen CVCs (Cook, Inc., Bloomington, IN, USA) were incubated in bacterial suspensions that contained bacteria at 10 6 cfu/mL in Trypticase soy broth to allow biofilm formation. After incubation at 378C for 24 h, segments were removed and excess broth was shaken off. Three catheter segments were rinsed and cultured to obtain a baseline value, and the remaining segments (three replicates per condition) were suspended for 24, 48, 72 and 96 h at 378C in one of the following treatment solutions: colistin (sulphate) alone, tigecycline alone, levofloxacin alone, clarithromycin alone, colistin/clarithromycin, colistin/ heparin, colistin/clarithromycin/heparin, tigecycline/clarithromycin, tigecycline/heparin, tigecycline/clarithromycin/heparin, levofloxacin/clarithromycin, levofloxacin/heparin and levofloxacin/clarithromycin/heparin. PBS was used as a control. Colistin, tigecycline and levofloxacin were used at concentrations of 400× MIC alone or in combination for the organisms tested in the planktonic phase. Clarithromycin was used at 200 mg/mL ( 100× serum concentration) and heparin was used at 1000 U/mL. Then, catheter segments were removed and washed 10 times with PBS to remove planktonic bacteria. These sections were individually sonicated for 10 min and vortexed for 30 s in 1 mL of PBS. After successive dilutions, if needed, all original sonication fluids were inoculated onto Trypticase soy agar plates (limit of detection, ,10 cfu) and the plates were incubated at 378C overnight. The median colony count of the three 1 cm sections was considered the representative value for that segment. 13 The experiments were repeated three times and the mean values for the biofilm bacteria were compared between groups for each antibiotic alone or in combination. The cfu/cm values of catheters for different groups were compared by one-way ANOVA followed by Bonferroni's multiple comparison test (GraphPad Software Inc., San Diego, CA, USA) and a P value of ,0.05 indicated significance.
Drug stability and compatibility
Each solution was incubated for 96 h and then evaluated for physical compatibility by particulate formation, colour change or gas evolution.
Results
The MICs of the antimicrobial agents for each of the planktonic forms of A. baumannii are shown in Table 1 . AB-19606 was susceptible to all antibiotics tested in this study, whereas AB-1 was resistant to levofloxacin. Clarithromycin, which is already not a therapeutic choice for A. baumannii infections, showed high MIC values.
Colistin at 400× MIC completely eradicated the AB-19606 and AB-1 biofilm bacteria within 3 days (Figure 1a and b) . In particular, AB-19606 and AB-1 biofilms were sterilized after 2 days of exposure to colistin/clarithromycin combinations. Although the colistin/heparin and colistin/clarithromycin/heparin combinations eradicated AB-1 within 3 days, the same combinations eradicated AB-19606 within 4 days.
Our catheter biofilms were not sterile within 4 days of exposure to 400× MIC tigecycline alone (Figure 1c and d) . Although tigecycline/clarithromycin completely eradicated AB-1 within 48 h, the same solution reduced viability .5 log but failed to eradicate AB-19606 bacteria embedded in biofilms. Similarly, tigecycline/clarithromycin/heparin achieved eradication of the biofilm of AB-1 at 96 h, whereas this combination only achieved a .5 log reduction in viable bacteria in AB-19606 biofilms during 2 -3 days of the lock period. The tigecycline/heparin combination did not eradicate AB-1 or AB-19606 biofilm bacteria within 4 days. However, bacterial viability in these two biofilms was significantly reduced by the combination compared with the control (P,0.05).
Two A. baumannii catheter biofilms were not eradicated by 400× MIC levofloxacin alone within 4 days of exposure (Figure 1e and f) . Levofloxacin at 400× MIC could kill AB-19606 and AB-1 by .5 log at 72 and 96 h, respectively, compared with the control (P,0.05). Although A. baumannii AB-1 was successfully eradicated by levofloxacin/clarithromycin and levofloxacin/clarithromycin/heparin combinations at 72 h, the same strain was not eradicated by the levofloxacin/heparin combination. On the other hand, for AB-19606, a .5 log reduction was achieved with the combination of levofloxacin/clarithromycin at 72 h and an approx. 5 log reduction was achieved with levofloxacin/clarithromycin/heparin and levofloxacin/heparin within 3 days of the lock period compared with the control (P,0.05).
Discussion
Although CVCs are increasingly used to save lives in ICUs and to administer medicine and fluids, 1 the use of CVCs may result in serious bloodstream infections. According to a clinical study by Krishnasami et al., 7 ALT was successful in achieving a clinical and bacteriological cure of dialysis CRB in 64.5% of patients, without requiring catheter replacement. Similarly, Funalleras et al.
14 suggested that ALT combined with a systemic antibiotic provided a 95% cure rate for 37 patients with Gram-negative bacteraemia.
According to our results, colistin alone was significantly more effective than tigecycline or levofloxacin for inhibiting A. baumannii organisms embedded in a biofilm (P,0.05). Colistin Ozbek and Mataraci at 400× MIC for a sufficient dwell time may be an option in catheters to prevent colonization and biofilm formation or to eliminate biofilm-embedded microorganisms. However, the use of tigecycline or levofloxacin alone might be associated with the regrowth of A. baumannii, so these drugs alone are not fully effective for preventing or eliminating the microbial burden of A. baumannii colonization in biofilms.
On the other hand, clarithromycin was found to be highly active in reducing A. baumannii colonization in biofilms on catheter segments compared with the control (P,0.05). Notably, clarithromycin was highly efficacious in enhancing the activities of all the antibiotics tested. These combinations involving clarithromycin acted more rapidly in reducing or eradicating both of the tested A. baumannii strains compared with the antibiotics tested alone. Figure 1 shows that colistin/clarithromycin killed biofilms of both A. baumannii strains within 2 days (3 days alone) and that tigecycline/clarithromycin and levofloxacin/clarithromycin could eradicate AB-1, which is an antimicrobial-resistant pathogen, within 2 and 3 days, respectively (no eradication when alone). Similarly, enhancement of the antibacterial activities of Comparative in vitro efficacies of various catheter lock solutions 829 JAC other antibiotics when combined with clarithromycin has previously been demonstrated against Staphylococcus aureus and Staphylococcus epidermidis bacteria embedded in biofilms. 15 -17 Additionally, Kandemir et al. 18 have shown that clarithromycin was the most common constituent of antibiotic combinations active against Pseudomonas aeruginosa in biofilms. Because this is the first investigation in which clarithromycin combinations were more effective in a lock solution to eradicate or reduce live cell numbers in biofilm formation in A. baumannii compared with the antibiotics used alone, additional studies are needed to investigate the mechanism of action of clarithromycin against A. baumannii biofilms.
Generally, ALT is used in conjunction with the administration of systemic antibacterial and/or anticoagulant agents to prevent thrombosis or obstruction of the catheter. 7, 19, 20 However, bacteria such as staphylococci may survive and grow in heparin-locked catheters. 19 We found that when heparin is included, combinations of colistin, tigecycline or levofloxacin were less effective than antibiotics used alone in ALT for A. baumannii biofilms (P .0.05). On the other hand, because ALT use also increases the frequency of catheter thrombosis, we evaluated our three antibiotics in combination with a clarithromycin/ heparin solution to assess the change in antimicrobial activity. Clarithromycin/heparin rarely reduced the antimicrobial effect of the antibiotics compared with when they were used alone. The interaction between the used antibiotics and heparin in catheter lock solutions needs to be evaluated in future studies.
In conclusion, colistin was significantly more active than tigecycline and levofloxacin against A. baumannii embedded in biofilms. Colistin, alone or in combination, eliminated and prevented the regrowth of organisms embedded in biofilms for 96 h and could be considered a most effective therapeutic option for the treatment or prevention of catheter-related infections due to A. baumannii.
Clarithromycin was highly effective when combined with the studied antibiotics to reduce the number of live cells of A. baumannii in biofilms. Notably, clarithromycin was efficacious in enhancing the activities of all the antibiotics tested. Our in vitro model findings about these solutions warrant clinical trials to investigate their real role in the management of CRB.
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